Compare Live Nation Entertainment, Inc. (LYV) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Live Nation Entertainment, Inc. vs Summit Therapeutics Inc — how do they compare? Live Nation Entertainment, Inc. trades at $172.16 (market cap $39.92B), while Summit Therapeutics Inc trades at $17.59 (market cap $13.71B). The key difference: Live Nation Entertainment, Inc. is far larger — about 2.9× Summit Therapeutics Inc's market cap, and Live Nation Entertainment, Inc. is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Live Nation Entertainment, Inc. for 72 Days and Summit Therapeutics Inc for 16 Days on average.
| LYV | SMMT | |
|---|---|---|
Market Cap | $39.92B | $13.71B |
Volume | 1,982,609 | 6,173,057 |
Sector | Media | Health |
52-Week High | $188.46 | $26.38 |
52-Week Low | $125.61 | $12.43 |
Typical Hold Time | 72 Days | 16 Days |
Enterprise Value | $42.13B | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LYV trades at $170.33, down 0.3% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported revenue of $25.20B in 2025, with net income of $496M, though margins remain thin at 1.96%. Recent news highlights strong fan demand and strategic partnerships, such as the Salesforce Agentforce expansion announced September 16, 2026. Analyst consensus is strongly bullish with a $208.18 price target, supported by 40 buy ratings.
The outlook for LYV is positive due to robust demand for live events and double-digit growth in deferred revenue, but risks include high valuation multiples, legal uncertainties from past DOJ scrutiny, and cost pressures. Earnings volatility is a concern after recent misses, though Q2 2026 beat expectations. Investors should weigh strong institutional support against execution risks in a competitive market.
Summit Therapeutics (SMMT) trades at $17.59, down 2.01% on the day, amid mixed earnings performance but strong analyst support with a consensus price target of $29.33. The stock shows a bullish technical signal from moving averages, with key support at $17 and resistance at $18. Recent news highlights a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, boosting investor optimism despite current negative profitability metrics.
The outlook for SMMT is heavily driven by clinical progress and partnerships, offering significant upside if drug trials succeed, but carries high risk due to substantial losses, negative cash flow from operations, and reliance on positive trial outcomes. Investors should weigh the potential rewards against the company's current financial health and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
